Pacira BioSciences (PCRX) Cash from Investing Activities Growth (3y) (2013 - 2026)
Pacira BioSciences (PCRX) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -53.63% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -55.36% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 34.35% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 33.61% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 15.92% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -2.45% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -36.76% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Pacira BioSciences | 970.37 Mn | 719.34 Mn | 148.24 Mn | 17.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.08% |
| Mar 31, 2026 | -33.53% |
| Dec 31, 2025 | 20.00% |
| Sep 30, 2025 | 42.90% |
| Jun 30, 2025 | 48.04% |
| Mar 31, 2025 | 50.24% |
| Dec 31, 2024 | -26.11% |
| Sep 30, 2024 | -14.14% |
| Jun 30, 2024 | -91.44% |
| Mar 31, 2024 | 34.66% |
| Dec 31, 2023 | 28.09% |
| Sep 30, 2023 | 72.23% |
| Jun 30, 2023 | -41.25% |
| Mar 31, 2023 | 62.83% |
| Dec 31, 2022 | 33.20% |
| Sep 30, 2022 | -118.61% |
| Jun 30, 2022 | 28.17% |
| Mar 31, 2022 | -66.92% |
| Dec 31, 2021 | 36.50% |
| Sep 30, 2021 | -33.35% |